Organoids as research models for hepatocellular carcinoma

Yu, Justin HY.; Ma, Stephanie

doi:10.1016/j.yexcr.2021.112987

Record: found
Abstract: not found
Article: not found

Organoids as research models for hepatocellular carcinoma

Author(s): Justin HY. Yu , Stephanie Ma

Publication date Created: February 2022

Publication date (Print): February 2022

Journal: Experimental Cell Research

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 115

Record: found
Abstract: not found
Article: not found

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Valérie Vilgrain, Peter Galle, Alejandro Forner … (2018)

0 comments Cited 2552 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S Finn, Shukui Qin, Masafumi Ikeda … (2020)

The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.

0 comments Cited 2404 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Min Ren, Silvija Kraljevic, Kenichi Saito … (2018)

In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma.